|Bid||0.00 x 1400|
|Ask||8.00 x 1100|
|Day's Range||6.85 - 7.76|
|52 Week Range||6.06 - 14.76|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 12, 2019 - Aug 12, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||21.00|
NEW YORK and VIENNA, Austria, Aug. 12, 2019 -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics, targeting infectious.
A look at the shareholders of HOOKIPA Pharma Inc. (NASDAQ:HOOK) can tell us which group is most powerful. Institutions...
Dow Jones futures: Illumina stock and profitable marijuana stock Innovative Industrial Properties fell late on news. An Amgen-Novartis Alzheimer's drug failed. Hookipa Pharma soared.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on July 11) Enlivex Therapeutics Ltd (NASDAQ: ENLV ) GALAPAGOS ...
Hookipa Pharma Inc. shares jumped 40% in late trading Thursday after the company announced that the Food and Drug Administration approved a study of the company's immunotherapy approach to certain cancers. Hookipa had asked the FDA for clearance on a phase 1/2 study of HB-201, and with its approval will now start its first clinical trial in immuno-oncology, the company said. "With the FDA's clearance of our IND application we have achieved an important milestone advancing HB-201 into clinical development," Chief Executive Joern Aldag said in the announcement. Hookipa, which went public in April, closed Thursday at $6.68, but shares neared $9.50 in after-hours trading following the announcement.
HOOKIPA Pharma Inc. (HOOK), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced that its Investigational New Drug (IND) Application for a Phase 1/2 clinical trial of HB-201, a TheraT®*-based immunotherapy, for the treatment of Human Papilloma Virus (HPV)-positive cancers is now effective following the clearance by the U.S. Food and Drug Administration (FDA). HB-201 (LCMV) is a TheraT®-based product candidate expressing a non-oncogenic but highly antigenic E6/E7 fusion protein derived from HPV16. HOOKIPA will now start a clinical trial with the goal to provide therapeutic benefit to patients with HPV16+ cancers.
Shares of Hookipa Pharma Inc. surged in after-hours trading Thursday after the company said the FDA approved an early stage trial of its treatment for human papilloma virus (HPV)-positive cancers. The company said in a statement that it intends to start the phase 1/2 clinical trial of its TheraT immunotherapy in the second half of 2019 with preliminary safety and efficacy data expected in late 2020 or early 2021. Human papilloma virus is estimated to cause about 5% of the worldwide burden of cancer including approximately 99% of cervical cancers, 25% to 60% of head and neck cancers, 70% of vaginal cancers and 88% of anal cancers, the company said.
VANCOUVER , June 10, 2019 /CNW/ - Agrios Global Holdings Ltd. (AGRO.CN) (OTCQB: AGGHF) (FSE: ØSA - WKN-A2N62K) ("Agrios" or the "Company") is pleased to announce that Chris Kennedy , President & CEO of Agrios will be presenting at the Advantage Strategy and Financial Conference (ASFC) on Friday June 14, 2019 , in Vienna, Austria . The conference showcases international companies with innovations in technology in many sectors including agri-tech, biotech and medical/pharmaceutical applications and products. Agrios is one of several presenters recognized for their development of ground-breaking technologies and products in the areas of agri-tech applications and data analytics that have been invited to present at the conference.
HOOKIPA Pharma Inc. (“HOOKIPA”), a company developing a new class of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform, today reported recent business highlights and financial results for the first quarter ended March 31, 2019. “HOOKIPA’s achievements since the start of 2019 have demonstrated our ability to execute and deliver on key company goals. Also, we now have the financial strength to achieve major milestones on our journey to translate great science into clinical programs.
HOOKIPA Pharma Inc. (HOOK), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced that it has achieved a further research milestone in its collaboration and license agreement with Gilead Sciences, Inc. (“Gilead”) for development of a therapeutic hepatitis B virus (HBV) vaccine. Based on the terms of the agreement, HOOKIPA is entitled to a milestone payment from Gilead. HOOKIPA has completed the research milestone for HBV by designing and delivering 10 research-grade vectors to Gilead, along with the characterization of these vectors and delivery of a data package for the HBV program.
HOOKIPA Pharma Inc. (HOOK), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced the appointment of David R. Kaufman, M.D., Ph.D., to its Board of Directors. Prior to joining the Institute, he held several leadership positions at Merck Research Laboratories, including Head of Translational Oncology, Executive Director in Clinical Oncology and Associate Director of the Merck Drug Development and Leadership Program. Dr. Kaufman is a member of the Board of Directors of the Society for Immunotherapy of Cancer (SITC), a not-for-profit medical professional society dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy.
NEW YORK, April 17, 2019 -- HOOKIPA Pharma Inc. (“HOOKIPA”), a company developing a new class of immunotherapeutics, targeting infectious diseases and cancers based on its.
For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . The IPO dates below are expected but not confirmed. Brainsway Ltd (BWAY) will issue 2.5 million shares at $11.94 Wednesday ...